Rights and permissions
About this article
Cite this article
Imatinib better value than IFN-α + low-dose cytarabine in CML. Pharmacoecon. Outcomes News 469, 6 (2005). https://doi.org/10.2165/00151234-200504690-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504690-00005